Evaxion significantly expands vaccine development collaboration with MSD
26 sept. 2024 07h30 HE
|
Evaxion Biotech
Agreement provides MSD with options to license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3Evaxion will host a conference call and webcast to discuss the agreement on...
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
29 mai 2024 02h00 HE
|
Anaveon
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
Proxygen Announces Collaboration and License Agreement with MSD for the Discovery and Development of Novel Molecular Glue Degraders
05 avr. 2023 07h00 HE
|
Proxygen
VIENNA, Austria, April 05, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, announced today a multi-year research collaboration and license...
Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer
16 mars 2021 08h00 HE
|
Immutep Limited
New Phase IIb trial called TACTI-003, to evaluate eftilagimod alpha in combination with MSD’s KEYTRUDA® (pembrolizumab) in 1st line head and neck squamous cell carcinoma (HNSCC)HNSCC is one of the...
Immutep Expands Part B of TACTI-002 Study
05 mars 2021 08h00 HE
|
Immutep Limited
Sydney, AUSTRALIA, March 05, 2021 (GLOBE NEWSWIRE) -- – Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases,...
Medical Society of Delaware Partners with HealthEC To Provide Population Health Platform to Nearly 900 Physicians
07 déc. 2017 09h37 HE
|
HealthEC
NEWARK, Del. and PISCATAWAY, N.J., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Medical Network Management Services of Delaware, LLC (MedNet), a wholly-owned subsidiary of the Medical Society of Delaware...